PMID: 7035495Feb 1, 1982Paper

Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus

The Journal of Clinical Investigation
C J BakerDennis L Kasper

Abstract

The opsonophagocytic requirements of human sera containing endogenous complement for a variety of type Ia, and group B streptococcal strains were defined. Significant reduction (>==90%) in colony-forming units was noted after a 40-min incubation for the highly encapsulated, mouse-passed prototype strain 090 by sera containing moderate to high concentrations of antibody to type Ia polysaccharide (mean, 16.5 mug/ml), whereas bacterial growth occurred in 25 sera with low levels of specific antibody (mean, 2.1 mug/ml). This absolute requirement for a critical amount of specific antibody in promoting opsonophagocytic killing of strain 090 was not found when 18 fresh clinical type Ia isolates were tested. In antibody-deficient and agammaglobulinemic sera, respectively, mean reductions in colony-forming units of 94 and 95% were seen for fresh clinical isolates, whereas strain 090 was not killed by polymorphonuclear leukocytes in the presence of these sera. All strains required a considerable amount of specific antibody for alternative pathway-mediated opsonophagocytosis. That opsonophagocytic killing of clinical type Ia isolates was mediated by the classical pathway in a nonantibody-dependent fashion was shown when MgEGTA chelation of...Continue Reading

References

Dec 1, 1976·The Journal of Clinical Investigation·V G HemmingH R Hill
Nov 1, 1977·The Journal of Infectious Diseases·P B Stewardson-KriegerS P Gotoff
Feb 1, 1979·The Journal of Experimental Medicine·D L KasperH J Jennings
Jul 1, 1979·The Journal of Infectious Diseases·R S BaltimoreJ Vecchitto
Feb 1, 1979·The Journal of Infectious Diseases·D L Kasper, C J Baker
Dec 1, 1979·The Journal of Infectious Diseases·M S EdwardsD L Kasper
Sep 1, 1979·Pediatric Research·C A DavisJ Forristal
Jan 1, 1972·The Journal of Clinical Investigation·E C GotschlichK J Sparks
Jun 1, 1966·The Journal of Hygiene·R C Lancefield, E H Freimer
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·H J JenningsD L Kasper
Apr 1, 1980·The Journal of Infectious Diseases·L C VogelC J Baker
Jan 1, 1980·Biology of the Neonate·J H Drew, C M Arroyave

❮ Previous
Next ❯

Citations

Aug 14, 2003·Molecular Immunology·Hanna JarvaSeppo Meri
Jan 1, 1986·The Journal of Pediatrics·C B Wilson
Nov 5, 1997·Immunity·L B KlicksteinA Nicholson-Weller
Feb 1, 1995·Molecular Microbiology·G S Tamura, C E Rubens
Nov 27, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Giampiero PietrocolaImmaculada Margarit
Dec 1, 1985·Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section C, Immunology·C SöderströmA G Sjöholm
Nov 1, 1992·Infection and Immunity·J R CampbellM S Edwards
Sep 1, 1989·Infection and Immunity·R ClaessonJ Carlsson
Mar 20, 1999·Infection and Immunity·S TakahashiJ F Bohnsack
Feb 1, 1983·Infection and Immunity·R A Broughton, C J Baker
Jun 1, 1983·Current Problems in Pediatrics·K L CatesM Ballow
Oct 1, 1986·Pathology·D L Gordon, M K Hostetter
Apr 25, 2017·Research in Microbiology·Piet Cools, Pierrette Melin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.